Welcome to our dedicated page for Ibio news (Ticker: IBIO), a resource for investors and traders seeking the latest updates and insights on Ibio stock.
iBio, Inc. develops AI-driven precision antibody therapies for cardiometabolic, obesity and cardiopulmonary diseases. Company news commonly covers pipeline updates for IBIO-600, a long-acting anti-myostatin monoclonal antibody, and IBIO-610, an Activin E antibody candidate, along with preclinical body-composition data and regulatory clearances tied to early clinical development.
Recurring updates also include iBio's antibody-discovery approach, including computational biology and epitope-steering, as well as financial results, capital financing, investor-conference presentations and board or committee changes.
iBio has announced its latest immune-oncology program targeting MUC16, a protein overexpressed in various solid tumors, including ovarian and pancreatic cancers. Utilizing its patented epitope steering AI platform, iBio's new monoclonal antibodies aim to bind to an unmodifiable region of MUC16, enhancing the effectiveness of cancer treatment by circumventing tumor evasion mechanisms. This addition expands iBio's immuno-oncology portfolio, which already includes programs targeting other cancer-specific proteins. The company emphasizes its commitment to advancing innovative treatments in the biopharmaceutical space.
iBio Inc. (NYSEA:IBIO) announced the issuance of U.S. Patent No. 11,545,238, which covers a machine learning model for designing engineered peptides aimed at improving therapeutic antibody precision. This patent reinforces iBio's leadership in AI-driven drug discovery and strengthens its competitive position in the biotech sector. The RubrYc Discovery Engine is highlighted as a key innovation, facilitating faster identification of effective molecules for challenging drug targets, particularly in hard-to-treat cancers.
iBio, Inc. (NYSEA: IBIO) has completed its public offering of 3,365,385 shares, along with Series A and Series B warrants, at a price of $1.04 each. The offering, partially exercised by underwriters, raised approximately $3.5 million in gross proceeds. Funds will primarily support operating costs, R&D, and general corporate needs. The Company aims to enhance its capabilities in developing new antibody treatments targeting challenging cancers and diseases. The offering was conducted under an SEC shelf registration statement effective since December 2020.
iBio, Inc. (NYSEA: IBIO) announced the pricing of an underwritten public offering of 3,365,385 shares at $1.04 each, with Series A and B warrants included. The offering aims to raise approximately $3.5 million for operating costs, particularly for research, development, and general corporate expenses, including employee payments. The closing is anticipated on or about December 9, 2022. Additionally, the underwriter has a 30-day option to purchase extra shares and warrants. This follows the company's effective shelf registration statement filed with the SEC.
iBio announced plans to conduct an underwritten public offering of common stock and Series A and B warrants, with a potential 30-day underwriter option for additional shares. The proceeds are aimed primarily at operating costs, including research and development and general corporate purposes. The offering, which is subject to market conditions, is associated with a shelf registration statement previously filed. H.C. Wainwright & Co. leads the offering management. iBio aims to strengthen its financial position while focusing on antibody development.
iBio, Inc. (NYSE: IBIO) announced that its Chief Scientific Officer, Martin Brenner, will participate in a virtual fireside chat at the JMP Securities Hematology and Oncology Summit on December 7, 2022, at 1:20 p.m. Eastern Time. The event will be broadcast live and archived on the company's website under the 'News & Events' section. iBio specializes in developing next-generation biopharmaceuticals utilizing computational biology to enhance antibody therapies for difficult-to-treat cancers and diseases.
iBio, Inc. (NYSE: IBIO) announced its participation in the Antibody Engineering & Therapeutics Conference 2022 in San Diego, presenting two posters highlighting applications of its AI-driven RubrYc Discovery Engine.
The presentations include AI-Designed Structural Immunogens targeting PD-1 Agonist and EGFRvIII tumor-specific epitopes. Additionally, they will showcase identification efforts of a potent PD-1 Agonist antibody and a targeted approach for tumor cells. The RubrYc Discovery Engine aims to develop effective immunotherapies for challenging cancers.
iBio, Inc. (NYSEA:IBIO) announces the immediate resignation of CEO Thomas F. Isett from both the Board of Directors and his executive duties. The current Chair, William (Chip) Clark, will oversee the leadership team during the search for a new CEO. Isett's contributions included enhancing iBio's portfolio and acquiring RubrYc’s drug discovery engine. The company emphasizes its commitment to developing innovative antibody treatments and maintaining its operations amidst leadership changes.
iBio, Inc. (NYSEA:IBIO) is divesting its contract development and manufacturing organization (CDMO) to focus on immuno-oncology assets and AI-driven drug discovery. This restructuring is expected to yield approximately 50% in annualized cost savings, reducing monthly expenses by $2.5-3.0 million. The divestiture process is aimed at advancing lead candidates like IBIO-101 and optimizing their proprietary technology, with expectations to complete the sale in 2023, contributing to a cash runway into mid-2024.
iBio has provided its preliminary unaudited financial results for the fiscal year ending June 30, 2022, reporting revenues of approximately $2.4 million, a slight increase of 1% from fiscal 2021. The company recorded a net loss of $50.3 million, expanding by $27.1 million due to rising R&D and administrative expenses. In a strategic move, iBio acquired assets from RubrYc Therapeutics, enhancing its immunotherapy portfolio. However, it has opted not to proceed with the IND submission for its COVID-19 vaccine candidate IBIO-202.